AMEIFAC Introduces Board of Directors
With hopes of further promoting clinical studies, analysis and dissemination of pharmaceutical, scientific, regulatory and pharmacovigilance information in Mexico, the Doctors and Pharmaceutical Professionals’ Association (AMEIFAC) has renewed its board of directors for the 2021-2023 period.
Incoming President, Manuel Lavariega, introduced the experts that will be taking on these leadership positions during a presentation event. Among the newly appointed were MBN’s interviewees Marlene Llópiz and Yolanda Cervantes as Head of the International Relations Commission and Juan Luis Serrano Leets as Head of the Regulatory, Government Relations and Authority Commission.
During the session, Lavariega proudly touted the many partnerships that AMEIFAC has consolidated with international associations such as the Academy of Physicians and Clinical Research, the International Federation of Associations of Pharmaceutical Physicians (IFAPP), the European Center of Pharmaceutical Medicine, among many others. As part of its partnership with IFAPP, AMEIFAC has been included in the January edition of IFAPP Today with the article “Clinical Trial Disruption: Getting Back on Track,” written by Llópiz.
At the national level, AMEIFAC looks forward to working with “sibling” associations, such as the Mexican Alliance of CROs (ACROM), the National Association of Drug Manufacturers (ANAFAM) and the Mexican Association of Pharmaceutical Innovation Industries (AMIIF). “With these partnerships, I hope we can achieve improvements for the pharmaceutical industry in Mexico,” said Lavariega.
AMEIFAC also counts CANIFARMA, Centro Médico Dalinde, Universidad Anáhuac and CINVESTAV among its allies, all of whom the association with medical professionals and through the validation of academic programs offered by AMEIFAC.
The new board hopes to provide recognition to professionals that attended every monthly meeting hosted by AMEIFAC and to academically support their efforts, among them to organize a national and international congress for professionals in the pharmaceutical industry. “We want to unite the different international associations to offer a high-quality event to educate our professionals,” said Lavariega.
“We are also very proud to announce that AMEIFAC will be offering two online certificate courses, one on pharmaceutical updates and the other on medical science liaisons updates,” shared Lavariega during the presentation.
AMEIFAC’s priorities for 2022 will be focused on digital transformation, pharmacovigilance, regulation of biological products, quality control, among others. The association will also introduce proposals on themes like AI and early access to innovative medicines at the national congress currently in the making.
AMEIFAC looks forward to expand its number of affiliates, offering exclusive access to academic content, discounts on certifications and free monthly meetings with decision-makers of the industry to talk about current events and trends.